IMR Press / FBS / Volume 12 / Issue 1 / DOI: 10.2741/S546

Frontiers in Bioscience-Scholar (FBS) is published by IMR Press from Volume 13 Issue 1 (2021). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with Frontiers in Bioscience.

Review
Epigenetic regulation as a promising tool for treatment of atherosclerosis
Show Less
1 Laboratory of Immunology and Cell Biotechnology, Immanuel Kant Baltic Federal University, Kaliningrad, Russian Federation, Russia
Send correspondence to: Daria Skuratovskaia, Laboratory of Immunology and Cell Biotechnology, Immanuel Kant Baltic Federal University, Kaliningrad, Russian Federation, Russia, Tel: 8-4012-595-595, E-mail: DSkuratovskaya@kantiana.ru
Front. Biosci. (Schol Ed) 2020, 12(1), 173–199; https://doi.org/10.2741/S546
Published: 1 March 2020
Abstract

Atherosclerosis is one of the leading causes of death from cardiovascular disease (CVD) that primarily involves mid size and large arteries. Atherosclerosis is associated with disruption of lipid metabolism and chronic inflammatory processes. One approach for treatment of atherosclerosis is by virtue of epigenetic control by noncoding RNAs (ncRNA) including miRNA, siRNA and lncRNA, commonly employing miRNA antagonists and mimic compounds. Here, we review such usages as well as other approaches for correcting the molecular lesions of atherosclerosis including specific activation of atheroprotective miRNAs, as well as use of siRNAs and lcRNA to control aberrant lipid metabolism. We also discuss some of these technologies that have already shown to be effective in clinical trials and are likely to enter the clinical arena.

Keywords
Atherosclerosis
miRNA
siRNA
lncRNA
Epigenetic
Review
Figures
Figure 1
Share
Back to top